JP4874959B2 - Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 - Google Patents

Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 Download PDF

Info

Publication number
JP4874959B2
JP4874959B2 JP2007515142A JP2007515142A JP4874959B2 JP 4874959 B2 JP4874959 B2 JP 4874959B2 JP 2007515142 A JP2007515142 A JP 2007515142A JP 2007515142 A JP2007515142 A JP 2007515142A JP 4874959 B2 JP4874959 B2 JP 4874959B2
Authority
JP
Japan
Prior art keywords
oxo
methyl
oxazine
dimethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501018A (ja
JP2008501018A5 (enExample
Inventor
ビー・ナラシムル・ナイドゥ
ジャック・バンヴィル
フランシス・ボーリュー
ティモシー・ピー・コノリー
マーク・アール・クリスタル
ジョン・ディ・マティスケラ
カール・ウレ
セルジュ・プラモンドン
ロジェ・レミラール
マーガレット・イー・ソレンソン
泰次 植田
マイケル・エイ・ウォーカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2008501018A publication Critical patent/JP2008501018A/ja
Publication of JP2008501018A5 publication Critical patent/JP2008501018A5/ja
Application granted granted Critical
Publication of JP4874959B2 publication Critical patent/JP4874959B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007515142A 2004-05-28 2005-05-12 Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 Expired - Fee Related JP4874959B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57551304P 2004-05-28 2004-05-28
US60/575,513 2004-05-28
US60337104P 2004-08-20 2004-08-20
US60/603,371 2004-08-20
US11/126,891 2005-05-11
US11/126,891 US7176196B2 (en) 2004-05-28 2005-05-11 Bicyclic heterocycles as HIV integrase inhibitors
PCT/US2005/016473 WO2005118593A1 (en) 2004-05-28 2005-05-12 Bicyclic heterocycles as hiv integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2008501018A JP2008501018A (ja) 2008-01-17
JP2008501018A5 JP2008501018A5 (enExample) 2008-06-19
JP4874959B2 true JP4874959B2 (ja) 2012-02-15

Family

ID=35456854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515142A Expired - Fee Related JP4874959B2 (ja) 2004-05-28 2005-05-12 Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環

Country Status (26)

Country Link
US (2) US7176196B2 (enExample)
EP (1) EP1749011B1 (enExample)
JP (1) JP4874959B2 (enExample)
KR (1) KR101097623B1 (enExample)
AR (1) AR049124A1 (enExample)
AT (1) ATE412656T1 (enExample)
AU (1) AU2005250356C1 (enExample)
BR (1) BRPI0511623A (enExample)
CA (1) CA2568356C (enExample)
CY (1) CY1110266T1 (enExample)
DE (1) DE602005010690D1 (enExample)
DK (1) DK1749011T3 (enExample)
ES (1) ES2315875T3 (enExample)
HR (1) HRP20090005T3 (enExample)
IL (1) IL179455A (enExample)
MX (1) MXPA06013835A (enExample)
NO (1) NO20065879L (enExample)
NZ (1) NZ551282A (enExample)
PE (1) PE20060242A1 (enExample)
PL (1) PL1749011T3 (enExample)
PT (1) PT1749011E (enExample)
RS (1) RS50700B (enExample)
RU (1) RU2381228C2 (enExample)
SI (1) SI1749011T1 (enExample)
TW (1) TWI366567B (enExample)
WO (1) WO2005118593A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007064502A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7897593B2 (en) * 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) * 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009120841A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
EP2349276B1 (en) * 2008-10-06 2019-11-27 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
US8383639B2 (en) * 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
KR20120094098A (ko) 2009-12-07 2012-08-23 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 피리디논 하이드록시사이클로펜틸 카복사미드: 치료 용도의 ｈｉｖ 인테그라제 억제제
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2807149A2 (en) * 2012-01-26 2014-12-03 CRO Consulting Limited Agents for treating neurodegenerative disorders
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
ES2656696T3 (es) 2013-05-17 2018-02-28 Merck Sharp & Dohme Corp. Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
WO2021050555A1 (en) * 2019-09-10 2021-03-18 X-Chem, Inc. Compositions and uses thereof
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7094783B2 (en) * 2002-06-26 2006-08-22 Bristol-Myers Squibb Company Bicyclic pyrimidinones as coagulation cascade inhibitors
AU2003292436B2 (en) 2002-12-27 2009-07-30 Msd Italia S.R.L. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
MX2007006637A (es) 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
EP1866313A1 (en) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors

Also Published As

Publication number Publication date
MXPA06013835A (es) 2007-02-02
IL179455A0 (en) 2007-05-15
SI1749011T1 (sl) 2009-08-31
PE20060242A1 (es) 2006-03-31
RU2006146970A (ru) 2008-07-10
WO2005118593A1 (en) 2005-12-15
US20050267105A1 (en) 2005-12-01
TW200600503A (en) 2006-01-01
RS50700B (sr) 2010-06-30
JP2008501018A (ja) 2008-01-17
RU2381228C2 (ru) 2010-02-10
TWI366567B (en) 2012-06-21
AR049124A1 (es) 2006-06-28
AU2005250356A1 (en) 2005-12-15
KR20070039502A (ko) 2007-04-12
PT1749011E (pt) 2008-11-27
NZ551282A (en) 2009-05-31
CA2568356A1 (en) 2005-12-15
KR101097623B1 (ko) 2011-12-22
CA2568356C (en) 2012-07-03
DK1749011T3 (da) 2009-02-16
AU2005250356C1 (en) 2011-10-06
CY1110266T1 (el) 2015-01-14
US20060276466A1 (en) 2006-12-07
EP1749011B1 (en) 2008-10-29
PL1749011T3 (pl) 2009-04-30
ES2315875T3 (es) 2009-04-01
NO20065879L (no) 2007-02-20
HK1107343A1 (en) 2008-04-03
ATE412656T1 (de) 2008-11-15
EP1749011A1 (en) 2007-02-07
DE602005010690D1 (de) 2008-12-11
US7511037B2 (en) 2009-03-31
IL179455A (en) 2011-10-31
US7176196B2 (en) 2007-02-13
HRP20090005T3 (hr) 2009-02-28
AU2005250356B2 (en) 2011-03-17
BRPI0511623A (pt) 2008-03-11

Similar Documents

Publication Publication Date Title
JP4874959B2 (ja) Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環
EP1948666B1 (en) Hiv integrase inhibitors
US20060199956A1 (en) Bicyclic heterocycles as HIV integrase inhibitors
WO2007143446A1 (en) Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
WO2008002959A2 (en) Hiv integrase inhibitors
JP2017503786A (ja) Ｎｒｆ２レギュレーター
JP2009515985A (ja) Ｈｉｖインテグラーゼインヒビター
JP2016516692A (ja) ヒト免疫不全ウイルス複製の阻害剤
WO2007059125A2 (en) Hiv integrase inhibitors
WO2007064316A1 (en) Bicyclic heterocycles as hiv integrase inhibitors
WO2007064619A1 (en) Pyrimidine derivatives as hiv integrase inhibitors
US7491819B1 (en) N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
WO2008154246A1 (en) Hiv integrase inhibitors
CN1989141B (zh) 作为hiv整合酶抑制剂的双环杂环
WO2007058646A1 (en) Hiv integrase inhibitors: cyclic pyrimidinone compounds
HK1107343B (en) Bicyclic heterocycles as hiv integrase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111124

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees